MedTrace Logo

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

NCT00849290 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2023-11-29

Study results available
· View outcomes & findings →

Summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Conditions

  • Metastatic Androgen Independent Prostate Cancer

Interventions

BIOLOGICAL

APC8015F

APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.

Sponsors & Collaborators

  • Dendreon

    lead INDUSTRY

Principal Investigators

  • Paul Schellhammer, MD · Devine Tidewater Urology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-01-31
Completion
2009-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849290 on ClinicalTrials.gov